Paysign director Henry buys $50,000 in common stock

Paysign director Daniel R. Henry purchased 10,084 shares of PAYS at a weighted average price of $4.9583 on June 16, 2025, totaling approximately $50,000, increasing his direct holdings to 129,884 shares. This acquisition follows strong performance from Paysign, including a 65% gain over the past six months, impressive Q1 2025 earnings with a 41% revenue increase, and expansion in its plasma donation center network, leading DA Davidson to raise its price target to $8.00.

Analysis

Paysign, Inc. (NASDAQ:PAYS) is exhibiting multiple positive catalysts, underscored by a recent insider purchase and strong fundamental performance. Director Daniel R. Henry's acquisition of 10,084 shares for approximately $50,000, increasing his holdings to 129,884 shares, signals strong internal confidence, particularly as the stock has already appreciated 65% over the past six months and currently trades at $5.12. This insider activity coincides with robust Q1 2025 financial results, where total revenue surged 41% year-over-year to $18.6 million, and earnings per share of $0.05 significantly surpassed the $0.01 forecast. Further bolstering the company's outlook is a strategic expansion of its plasma donation center network by 132 centers, now totaling 615, which is projected to capture approximately 50% of the U.S. market share and drive immediate revenue growth without a corresponding increase in SG&A expenses, indicating strong operating leverage. This operational strength and growth trajectory prompted DA Davidson to successively raise its price target, first to $6.00 post-earnings, and then to $8.00, citing the plasma industry expansion. Despite the recent share price rally, InvestingPro data suggests the company, valued at $278 million, is trading near its Fair Value, with analysts anticipating profit growth for the current year.

Key Decisions for Investors

• Investors should consider the strong signals from insider buying and recent operational outperformance, including a 41% Q1 revenue increase and significant EPS beat, as indicative of robust company health and management confidence.
• The strategic expansion in the plasma donation network, expected to boost revenue without increasing SG&A, alongside DA Davidson's revised $8.00 price target, suggests potential for further share price appreciation, although the stock's 65% gain in six months and current trading near its fair value warrant careful consideration of entry points.
• Monitor upcoming quarterly reports for sustained revenue growth and margin improvement resulting from the network expansion to validate the projected operating leverage and continued execution of Paysign's growth strategy.